Log In

Forgot Password?
Create New Account

Loading... please wait

2022 Annual Meeting | Industry Therapeutic Update from Genentech: The Trends Shaping the Future of Alzheimer's Research

Wednesday 04/06/22
07:00 PM - 10:00 PM PDT Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Diana R. Kerwin, MD
General Neurology
The Alzheimer's disease landscape and patient journey are evolving rapidly. Join an expert panel as they discuss key trends shaping this future, including ways of addressing health disparities and diversity in clinical trials, overcoming challenges in earlier detection and diagnosis, and the role of brain health in risk reduction and prevention. We hope this exciting and dynamic discussion will deliver key learnings that are relevant to both your practice and your patients.
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. 
The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
0.00 credit

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT Speaker Industry Therapeutic Update from Genentech: The Trends Shaping the Future of Alzheimer's Research
Faculty Disclosures
Diana R. Kerwin, MD Diana Kerwin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Diana Kerwin has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Diana Kerwin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Diana Kerwin has received research support from NIH. The institution of Diana Kerwin has received research support from Lilly. The institution of Diana Kerwin has received research support from Global Alzheimer's Platform. The institution of Diana Kerwin has received research support from AbbVie.
Gary W. Small, MD No disclosure on file
Tammie Benzinger Tammie Benzinger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Tammie Benzinger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Tammie Benzinger has received personal compensation in the range of $0-$499 for serving as a Consultant for Sora Neuroscience. The institution of Tammie Benzinger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Siemens. Tammie Benzinger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Tammie Benzinger has a non-compensated relationship as a Consultant with Siemens that is relevant to AAN interests or activities. Tammie Benzinger has a non-compensated relationship as a Consultant with Eisai that is relevant to AAN interests or activities.
Nancy Lynn, Other Ms. Lynn has nothing to disclose.